Search results
Showing 286 to 300 of 868 results for score
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands (MIB29)
NICE has developed a medtech innovation briefing (MIB) on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands
Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion (HTG161)
Evidence-based recommendations on laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. This involves using a special laser device to create a bypass without the need to temporarily interrupt the blood flow to the brain.
View recommendations for HTG161Show all sections
Sections for HTG161
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (HTG129)
Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.
View recommendations for HTG129Show all sections
Sections for HTG129
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults
Endoscopic thoracic sympathectomy for primary facial blushing (HTG331)
Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis (MIB317)
NICE has developed a medtech innovation briefing (MIB) on LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis .
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
Patient Status Engine for wireless monitoring of vital signs (MIB271)
NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.